La Trobe Institute for Molecular Science

Cadence Expands Pfizer’s License to Molecular Design Software

Retrieved on: 
Wednesday, October 25, 2023
Biotechnology, Technology, Health, Pharmaceutical, Semiconductor, Other Science, Software, Artificial Intelligence, Science, Hardware, Electronic Design Automation, Cadence Design Systems, Digital, Cheminformatics, OpenEye Scientific Software, La Trobe Institute for Molecular Science, Doctor of Philosophy, Research, Pharmaceutical industry, Pfizer

Cadence Molecular Sciences (OpenEye)—a business unit of Cadence Design Systems (Nasdaq: CDNS)—announced today that Pfizer Inc. has signed an agreement to extend and expand access to Cadence® products and programming toolkits for advanced molecular design.

Key Points: 
  • Cadence Molecular Sciences (OpenEye)—a business unit of Cadence Design Systems (Nasdaq: CDNS)—announced today that Pfizer Inc. has signed an agreement to extend and expand access to Cadence® products and programming toolkits for advanced molecular design.
  • “We’re excited to continue to support Pfizer as they innovate across their therapeutic portfolio, utilizing this unique set of research tools to aid in their early-stage drug discovery process,” said Anthony Nicholls, PhD, corporate vice president, Cadence Molecular Sciences.
  • The software is used by major pharmaceutical and biotech companies worldwide to help accelerate and advance therapeutic research.
  • To learn more about Cadence Molecular Sciences (OpenEye) and its technologies, please visit https://www.cadence.com/openeye .

Nutromics attracts world leaders in the emerging field of DNA-based sensing to join its Biosensor Advisory Board

Retrieved on: 
Friday, July 28, 2023
Columbia University, Scientia, University, Thomson Reuters, Johns Hopkins School of Medicine, Believer, Protein folding, University of California, Associate, Biology, Johns Hopkins University, Department of Chemistry, University of Manchester, Johns Hopkins, University of North Carolina at Chapel Hill, La Trobe Institute for Molecular Science, Pharmaceutical industry, Medical imaging, Chemistry, Pharmacology

Nutromics is a leader in continuous DNA-based sensing and is developing the world's first precision diagnostic platform.

Key Points: 
  • Nutromics is a leader in continuous DNA-based sensing and is developing the world's first precision diagnostic platform.
  • The board consists of researchers from Columbia University, University of California, Johns Hopkins, North Carolina State University, and the University of New South Wales.
  • "We've attracted the most acclaimed researchers in the field because we're world leaders in the space of continuous DNA-based sensing," said Nutromics CEO and co-founder Peter Vranes.
  • To achieve this, we need to collaborate with the most experienced experts, and this advisory board represents a major step in that direction."

Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases

Retrieved on: 
Wednesday, April 12, 2023
Central nervous system, Autophagy, AMD, Geographic atrophy, DLB, Cognition, Head, Research, Dementia, Oxidative stress, International Journal of Molecular Sciences, Canadian International Council, Synapse, Lewy body, Therapy, La Trobe Institute for Molecular Science, Pharmaceutical industry

NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) announced that a review article titled, “Sigma-2 Receptors – From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases” ( doi.org/10.3390/ijms24076251 ) was published online in the International Journal of Molecular Sciences.

Key Points: 
  • NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) announced that a review article titled, “Sigma-2 Receptors – From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases” ( doi.org/10.3390/ijms24076251 ) was published online in the International Journal of Molecular Sciences.
  • This peer-reviewed publication summarizes the current evidence-based understanding of sigma-2 (σ-2) receptor biology and function, and its potential as a therapeutic target for age-related degenerative diseases of the central nervous system, including Alzheimer’s disease, α-synucleinopathies such as dementia with Lewy bodies (DLB), and dry age-related macular degeneration.
  • “Cognition Therapeutics has pioneered the development of oral small molecules targeting the σ-2 receptor since our founders first discovered that σ-2 ligands rescue key aspects of neuronal functioning in models of Alzheimer’s disease,” explained Mary Hamby, Ph.D. , VP of research at Cognition Therapeutics.
  • Anthony O. Caggiano, M.D., Ph.D. , Cognition Therapeutics’ chief medical officer and head of R&D, concluded, “We are excited that Cognition Therapeutics’ novel, proprietary strategy of using oral σ-2 modulators to protect synapses and retinal cells may offer a distinct new mechanism to slow progression in these and potentially other diseases with enormous unmet medical need.”
    The review article is available via open access at doi.org/10.3390/ijms24076251 and on our website on the Cognition Therapeutics Publications webpage.

RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome

Retrieved on: 
Wednesday, February 15, 2023
TEL, ARS, Radiation damage, Bone marrow, Canadian International Council, Priority review, International Journal of Molecular Sciences, Food, Acute radiation syndrome, Apsis, La Trobe Institute for Molecular Science, Radiation, Survival, FDA, Homeland, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doctor of Philosophy, MD, Pharmaceutical industry

"We are pleased to align with the FDA on the Animal Rule development pathway for opaganib for ARS.

Key Points: 
  • "We are pleased to align with the FDA on the Animal Rule development pathway for opaganib for ARS.
  • "Given the promising data already generated with opaganib for ARS, we are set to continue collaborating with a range of U.S. agencies in addition to discussions with other governments."
  • In the relevant study models, opaganib was associated with protection of normal tissue, including gastrointestinal tissue, from radiation damage due to ionizing radiation exposure or cancer radiotherapy.
  • Opaganib, an oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute, supporting, if approved, potential central government stockpiling for use in mass casualty nuclear radiation incidents.

RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published

Retrieved on: 
Monday, November 14, 2022
Cell, Awareness, Thallium, Literature, Acceleration, Half-life, Caesium, Americium, Infection, TBI, International Journal of Molecular Sciences, La Trobe Institute for Molecular Science, Face, Strategic National Stockpile, Radiation, Survival, Government, Radiation exposure, B cell, Iodine, FDA, Filgrastim, Apsis, TEL, Chemoradiotherapy, Head, Mouse, Acute radiation syndrome, TNF, Total body irradiation, Safety, Extrapyramidal system, Nutrient, Toxicity, Inflammation, Homeland, Redhill, Chronic radiation syndrome, Opaganib, Plutonium, Animal, DTPA, Stem cell, Company, Nasdaq, Potassium iodide, Canadian International Council, Disease, Radiation damage, COVID-19, Bone marrow, Curium, MCM, Medical imaging, Pharmaceutical industry, Food preservation, Prussian blue (disambiguation)

The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.

Key Points: 
  • The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.
  • Much of the damage caused by radiation exposure is caused by inflammation secondary to the effects of ionizing radiation itself known as Acute Radiation Syndrome.
  • Again, opaganib was not associated with a diminished tumor response to fractionated radiation treatment and increased weight loss from radiation treatment was not observed.
  • Data from the opaganib global Phase 2/3 study has been submitted for peer review and recently published in medRxiv .

CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate

Retrieved on: 
Thursday, September 29, 2022
International Journal of Molecular Sciences, Tel Aviv Sourasky Medical Center, Time, Policy, Twitter, MD, Canadian International Council, Drug, Ministry, OTCQB, Company, LinkedIn, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, Polyp (medicine), Government, Exchange, Cancer, Effect, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Instagram, Report, Collection, La Trobe Institute for Molecular Science, Security (finance), Ministry of Health and Medical Education, Pharmaceutical industry

Study design included collection of both polypoid tissue biopsies and healthy colonic tissue biopsies from 22 patients.

Key Points: 
  • Study design included collection of both polypoid tissue biopsies and healthy colonic tissue biopsies from 22 patients.
  • CNBX Pharmaceuticals is currently developing its proprietary Drug Candidate PLP-33 for the treatment of colonic polyps.
  • CNBX Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine.
  • For the latest updates on CNBX Pharmaceuticals follow the Company on Twitter @cnbxpharma, Facebook @cnbxPharmaceuticals, LinkedIn, and on Instagram @CNBX_Pharmaceuticals.

Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients

Retrieved on: 
Monday, August 29, 2022
COVID-19, HIV disease progression rates, Swiss, Safety, Hospital, Research, MAPK, Therapy, Canadian International Council, Disease, Swiss Federal Nuclear Safety Inspectorate, La Trobe Institute for Molecular Science, VOC, Public health, United States Medical Licensing Examination, International Journal of Molecular Sciences, Patent, Severe acute respiratory syndrome coronavirus 2, MBA, Pioglitazone, Probability, Patient, Omicron, FDA, KNRS, Knowledge, Drug development, Federal Council, Swiss Federal Council election, Pharmaceutical industry, Muthiri kinaru

The trial will enroll patients at clinical trial sites in Switzerland and Germany.

Key Points: 
  • The trial will enroll patients at clinical trial sites in Switzerland and Germany.
  • The KINFAST trial is partly supported by a non-diluting grant from the Programme for COVID-19 medicines of the Swiss Federal Office of Public Health.
  • Kinarus previously provided an update on progress of its first Phase 2 clinical trial of KIN001 to treat hospitalized COVID-19 patients (KINETIC).
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19

Retrieved on: 
Monday, August 22, 2022
COVID-19, CEO, Research, MAPK, Swiss National Bank, Canadian International Council, Disease, La Trobe Institute for Molecular Science, VOC, Infection, United States Medical Licensing Examination, International Journal of Molecular Sciences, Federal Council of Engineering and Agronomy, Patent, Severe acute respiratory syndrome coronavirus 2, MBA, Pioglitazone, Probability, CET, Omicron, Therapy, KNRS, Knowledge, Drug development, Federal Council, Patient, Pharmaceutical industry, Muthiri kinaru

The webinar will feature a presentation by Dr. Thierry Fumeaux M.D., MBA, Chief Medical Officer of Kinarus and former Chairman of the Swiss National COVID-19 Scientific Task Force mandated by the Federal Council.

Key Points: 
  • The webinar will feature a presentation by Dr. Thierry Fumeaux M.D., MBA, Chief Medical Officer of Kinarus and former Chairman of the Swiss National COVID-19 Scientific Task Force mandated by the Federal Council.
  • Kinarus expects interim data from its first Phase 2 clinical trial of KIN001 to treat hospitalized COVID-19 patients (KINETIC) to be available late in Q3 2022.
  • Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland.
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Panavance Therapeutics Announces Publication of Promising Preclinical Data Evaluating GP-2250 for the Treatment of Malignant Peritoneal Mesothelioma

Retrieved on: 
Monday, August 8, 2022
FDA, Apoptosis, Mesothelioma, Respiration (physiology), CEO, Forward-looking statement, GLOBE, La Trobe Institute for Molecular Science, Population, Breast, Synergy, Cancer, Cisplatin, Flow cytometry, ST, Quality of life, Patient, University of Duisburg-Essen, Therapy, Company, International Journal of Molecular Sciences, Pancreatic cancer, Organ (anatomy), Manuscript, General officer, Canadian International Council, Mitomycin C, Melanoma, University, Ovarian cancer, Ruhr University Bochum, Necrosis, Pharmaceutical industry, Panaveli

BERWYN, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic designed to disrupt cancer’s energy metabolism and improve quality of life for patients, today announced the publication of positive preclinical data from a 3-D in vitro study evaluating GP-2250 for the treatment of malignant peritoneal mesothelioma. The manuscript titled, “Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study1,” was published in the peer-reviewed journal, International Journal of Molecular Sciences. 

Key Points: 
  • This preclinical study is the first to investigate effects of the novel agent GP-2250 on malignant mesothelioma.
  • As we progress its development for the treatment of pancreatic ductal adenocarcinoma, amassing a growing body of data provides valuable validation and guidance.
  • We look forward to further exploring the potential of GP-2250, commented Greg Bosch, Chairman and CEO of Panavance Therapeutics.
  • GP-2250 showed promising antineoplastic effects on malignant mesothelioma cells in vitro especially in combination with cisplatin/mitomycin C even when used at lower concentrations.

Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic

Retrieved on: 
Tuesday, June 28, 2022
Atlas Shrugged: Part I, FDA, Annual report, PMI, Bone marrow suppression, Patient, ORR, Rectum, Retinal detachment, Neuroblastoma, File, GLOBE, Ix, Colorectal cancer, COVID-19, Anatomy, Union, Sulindac, Eflornithine, PD-1, Cancer, NSCLC, MSN, Fibroadenoma, Risk, Overalls, Therapy, Colon, Neoplasm, FAP, La Trobe Institute for Molecular Science, Nasdaq, Type 1, Private Securities Litigation Reform Act, Stomach, Peripheral neuropathy, Doctor of Philosophy, Survival, Polyamine, International Journal of Molecular Sciences, Retinopathy, Canadian International Council, Large-cell lung carcinoma, Safety, Ovarian cancer, Forward-looking statement, Birth control, Pharmaceutical industry

Data published in the International Journal of Molecular Sciences also showed SBP-101 delayed tumor progression and decreased the overall tumor burden.

Key Points: 
  • Data published in the International Journal of Molecular Sciences also showed SBP-101 delayed tumor progression and decreased the overall tumor burden.
  • This data highlights the importance of polyamines as a cancer therapeutic.
  • We look to expand SBP-101 into ovarian cancer, and later the potential for other cancers.
  • Forward-looking statements can be identified by words such as: believe, design, expect, feel, intend, may, plan, scheduled, and will.